touchMDT for touchONCOLOGY - What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)?

touchPODCAST

Contenido proporcionado por touchpodcast. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente touchpodcast o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

3M ago 15:14

MP3•Episodio en casa

touchMDT for touchONCOLOGY

What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)?

Listen to key experts Prof. Suresh Senan, Dr Lizza Hendriks and Dr Jacob Sands discuss the impact of ICIs on the real-world management of patients with LS-SCLC, including guidance on monitoring for and management of possible immune-related side effects.

The multidisciplinary team

Radiation oncologist – Prof. Suresh Senan
Amsterdam University Medical Center, Amsterdam, The Netherlands

Pulmonologist – Dr Lizza Hendriks,
Maastricht University Medical Center, Maastricht, The Netherlands

Medical oncologist – Dr Jacob Sands
Dana-Farber Cancer Institute, Boston, MA, USA

This touchPODCAST is for HCPs outside the UK.

This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our website:
https://touchoncologyime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/

102 episodios

#Science #TouchPODCAST